Elpida Therapeutics

Focus: Elpida Therapeutics is a public biotechnology company focused on gene therapy for rare diseases, particularly neurological and neuromuscular conditions. The company operates at a modest scale with a concentrated pipeline in early-to-mid stage development.

Rare Diseases Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Elpida Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Elpida Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Ty

Peripheral Neuropathy

N/A

Clinical Trials (1)

NCT06151600A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J

N/A

Help build intelligence for Elpida Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focus on rare disease gene therapy offers meaningful impact on underserved patient populations with limited treatment options.
Public company status provides liquidity, institutional credibility, and potential for stock-based compensation upside.
Diversified pipeline across multiple rare neurological indications (hereditary spastic paraplegia, CMT-4J, Lafora disease) reduces single-asset risk.

Watch Out For

Zero active job openings at the time of this analysis suggests limited hiring or potential organizational contraction.
Early-stage pipeline (3 Phase 1/2 programs, 1 Phase 3) carries high clinical failure risk with limited near-term revenue catalysts.
Missing financial data (revenue, R&D spend, cash position) raises transparency concerns about company health and sustainability.

Generated by Claude from Elpida Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MELPIDA

Spasticity, Muscle

Phase 1/2

Clinical Trials (1)

NCT05518188Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)

Phase 1/2

ELP-02

Charcot-Marie-Tooth Disease Type 4J

Phase 1/2

Clinical Trials (1)

NCT07447557Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)

Phase 1/2